Combination therapy for the treatment of cancer

A method of treating or managing newly diagnosed multiple myeloma, comprising administering to a patient having the newly diagnosed multiple myeloma a (i) Compound A

• or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in an amount of from about 0.5 to about 5 mg per day, (ii) daratumumab and (iii) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

A method for treating or managing newly diagnosed multiple myeloma, comprising:

• (i) identifying a patient having the newly diagnosed multiple myeloma sensitive to treatment with (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and (b) daratumumab;
• and
• (ii) administering to the patient (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in an amount of from about 0.5 to about 5 mg per day and (b) daratumumab.

A method for treating or managing newly diagnosed multiple myeloma, comprising:

• (i) identifying a patient having the newly diagnosed multiple myeloma sensitive to treatment with (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof (b) daratumumab and (c) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof;
• and
• (ii) administering to the patient (a) Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in an amount of from about 0.5 to about 5 mg per day (b) daratumumab and (c) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.